Taiwan High Speed Rail Corp (THSRC, 台灣高鐵) said yesterday that the three independent directors on its board had agreed to halve their salaries amid a public uproar over their high pay when the company’s finances remain firmly in the red.
The company said in a statement that its board held a meeting yesterday at which independent directors Lin Chen-kuo (林振國), Victor Liu (劉維琪) and George Chen (陳世圯) voluntarily agreed to cut their basic annual salaries to NT$900,000 (US$28,000) from NT$1.8 million.
THSRC said the cut in basic salaries would be retroactive to January this year, according to the statement.
The three independent directors, appointed by the government to sit on the rail company’s board, have been called “government fat cats” and criticized for being simultaneously paid by multiple public agencies.
While the government had asked the company to solve the issue as soon as possible, THSRC failed to address the matter at its annual general meeting last month, even though both Liu and Chen later told local media that they would be willing to have their salaries halved or even do their jobs for free.
Lin will still earn NT$1.62 million a year at THSRC as he also chairs the company’s audit committee, which pays him NT$720,000 a year. Both Liu and Chen will make NT$1.26 million each a year, as Liu heads the firm’s finance committee, for which he receives an annual salary of NT$360,000 and Chen the corporate governance committee, which also provides annual compensation of NT$360,000.
MOVING ON UP: Taiwan improved in all four areas measured by the IMD, making its biggest leap, from 17th to sixth place, in economic performance Taiwan moved up three spots from last year to place eighth, its best performance since 2013, in the latest annual world competitiveness rankings, released yesterday by the International Institute for Management Development (IMD). Innovation, digitalization, welfare benefits and social cohesion are critical to economic performance, with Switzerland, Sweden, Denmark, the Netherlands and Singapore making up the top five on the list this year, the Switzerland-based institute said, after grading 64 countries and regions based on economic performance, infrastructure, and government and business efficiency. “Leading performers are characterized by varying degrees of investment in innovation, diversified economic activities and supportive public policy,” IMD
With the US opening up to travel, demand in Taiwan for US-bound flights has soared, pushing up ticket prices to most destinations in North America, tourism sources said. Fares for destinations in the US have risen dramatically since the middle of last month, and the trend is expected to continue in the coming months, as California on Tuesday lifted most social distancing and capacity limits put in place to contain the spread of COVID-19, ezTravel Co (易遊網) said in a statement yesterday. The travel agency forecast that the number of tickets sold this month is likely to be double or triple
‘MATTER OF SURVIVAL’: Vice Premier Liu He is to lead the development of ‘third-generation’ chips, a field not yet dominated by any nation or company Chinese President Xi Jinping (習近平) is renewing his years-long push to achieve technology self-sufficiency by tapping a top deputy to shepherd a key initiative aimed at helping domestic chipmakers overcome US sanctions. Chinese Vice Premier Liu He (劉鶴), Xi’s economic czar whose sprawling portfolio spans trade to finance and technology, has been tapped to spearhead the development of so-called “third-generation” chip development and capabilities, and is leading the formulation of a series of financial and policy supports for the technology, people with knowledge of the matter said. It is a nascent field that relies on newer materials and gear beyond traditional silicon,
OPPORTUNITY: The company aims to sell its product soon, as enterovirus vaccines are not available anywhere but China, where firms are only marketing their vaccines locally Medigen Vaccine Biologics Corp’s (高端疫苗) phase 3 clinical trials for an enterovirus 71 (EV71) vaccine completed the multi-regional, multi-central data “unblinding” yesterday, with the results, including safety, immunogenicity and efficacy, meeting its expectations. The company would compile a final analysis report as soon as possible, and apply for the new drug certificate from domestic and foreign drug authorities in the third quarter, Medigen said in a Taiwan Stock Exchange filing yesterday. Its phase 3 trials were conducted in Taiwan and Vietnam with 3,049 participants ranging from two months old to six years old, Medigen said. The company enrolled its first participant for